Pancreatic Cancer Research

ResearcherKing's College LondonActive in the last 2 years

Shailesh Vinayak Shrikhande

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8036-4212; OpenAlex author ID A5036258878, A5111853118, A5113518183. Sources: OpenAlex.

Their work

Papers
35 (first author 1, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
116
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 6 papers · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 5 papers · 2025: 5 papers · 2026: 4 papers

Papers 35

  1. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  2. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  3. Financial toxicity among gastric and pancreatic cancer survivors in India and its impact on quality of life. Last author DOI 10.1016/j.jcpo.2026.100730↗
  4. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  5. Utility of Surgical Apgar Score in Predicting Post-operative Complications After Whipple Procedure in Pancreatic Cancer Patients. Last author DOI 10.1007/s13193-024-02151-1↗
  6. Financial burden due to distance traveled to access treatment from specialized cancer hospitals in public sector in India: a case study of patients treated for… Co-author DOI 10.1016/j.jcpo.2025.100632↗
  7. Quality assurance of surgical interventions for pancreatic cancer: systematic review of multicentre randomized clinical trials. Co-author DOI 10.1093/bjsopen/zraf082↗
  8. Periarterial Divestment and Triangle Clearance in Pancreatic Cancer: A Video Vignette. Co-author DOI 10.1245/s10434-024-16542-9↗
  9. ASO Author Reflections: Arterial Divestment: A Viable and Safe Option for Resection of Locally Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-025-16924-7↗
  10. Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer. First author DOI 10.1007/s13193-021-01361-1↗
  11. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  12. Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2024.06.004↗
  13. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  14. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  15. Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Multicentre Indian Pancreatic & Periampull… Co-author DOI 10.1007/s12029-023-00936-1↗
  16. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence. Last author DOI 10.1016/j.surg.2021.10.018↗
  17. Minimally invasive surgery for pancreatic cancer-are we there yet?-a narrative review. Last author DOI 10.21037/cco-21-131↗
  18. Twelve Hundred Consecutive Pancreato-Duodenectomies from Single Centre: Impact of Centre of Excellence on Pancreatic Cancer Surgery Across India. Co-author DOI 10.1007/s00268-019-05235-0↗
  19. Correction to: Twelve Hundred Consecutive Pancreato-Duodenectomies from Single Centre: Impact of Centre of Excellence on Pancreatic Cancer Surgery Across India. Co-author DOI 10.1007/s00268-020-05519-w↗
  20. Cutting-edge strategies for borderline resectable pancreatic cancer. Last author DOI 10.1002/ags3.12254↗
  21. Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Co-author DOI 10.1097/sla.0000000000002633↗
  22. Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors. Last author DOI 10.1007/s00423-018-1653-6↗
  23. Improved Outcomes in 394 Pancreatic Cancer Resections: the Impact of Enhanced Recovery Pathway. Last author DOI 10.1007/s11605-018-3809-7↗
  24. Financial Impact of Complex Cancer Surgery in India: A Study of Pancreatic Cancer. Last author DOI 10.1200/jgo.17.00151↗
  25. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview. Co-author DOI 10.2174/1389202919666180221160753↗
  26. Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients? Last author DOI 10.4103/ijc.ijc_552_17↗
  27. Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Co-author DOI 10.4103/ijmr.ijmr_249_17↗
  28. Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. Last author DOI 10.4103/ijc.ijc_377_17↗
  29. Advances in chemotherapy for pancreatic cancer. Last author DOI 10.1007/s13193-014-0371-y↗
  30. Treatment of patients with metastatic pancreatic cancer: Experience from a tertiary Indian cancer center. Last author DOI 10.4103/0019-509x.176732↗
  31. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  32. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  33. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Co-author DOI 10.1016/j.surg.2014.06.016↗
  34. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature. Co-author DOI 10.1111/j.1477-2574.2012.00508.x↗
  35. Metastatic pancreatic cancer: another option? Co-author PMID 22680261↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Manish Suresh BHANDARE · 14 shared papers, 2018–2026 · strength 3.00
  2. Vikram Anil Chaudhari · 10 shared papers, 2018–2025 · strength 1.90
  3. Vikas S. Ostwal · 7 shared papers, 2017–2024 · strength 0.79
  4. Shravan Nadkarni · 2 shared papers, 2025 · strength 0.73
  5. Anant Ramaswamy · 6 shared papers, 2017–2024 · strength 0.72
  6. Bhawna Sirohi · 5 shared papers, 2015–2024 · strength 0.71
  7. Vandana Agarwal · 4 shared papers, 2018–2025 · strength 0.62
  8. Savio George Barreto · 2 shared papers, 2012–2024 · strength 0.41
  9. Marc G. Besselink · 3 shared papers, 2019–2026 · strength 0.40
  10. Rajesh S. Shinde · 3 shared papers, 2019–2020 · strength 0.39
  11. Abhishek Mitra · 4 shared papers, 2018–2022 · strength 0.38
  12. Abhishek Anand · 1 shared paper, 2026 · strength 0.36
  13. Matthew H. G. Katz · 2 shared papers, 2024–2026 · strength 0.33
  14. Thilo Hackert · 2 shared papers, 2024–2026 · strength 0.33
  15. Giovanni Marchegiani · 2 shared papers, 2024–2026 · strength 0.33
  16. Mohit Pandey · 1 shared paper, 2025 · strength 0.33
  17. Nilanjana Howbora · 1 shared paper, 2025 · strength 0.28
  18. Vijaya P. Borkar Patil · 1 shared paper, 2025 · strength 0.28
  19. Christopher Lee Wolfgang · 2 shared papers, 2019–2026 · strength 0.27
  20. Jin‐Young Jang · 2 shared papers, 2019–2026 · strength 0.27
  21. Samir Pathak · 1 shared paper, 2025 · strength 0.26
  22. Jack A. Helliwell · 1 shared paper, 2025 · strength 0.26
  23. Andrew Malvern Smith · 1 shared paper, 2025 · strength 0.26
  24. Markus Wolfgang Büchler · 4 shared papers, 2014–2024 · strength 0.22
  25. Rutger T. Theijse · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.